» Articles » PMID: 37394578

Cancer-associated Fibroblasts: from Basic Science to Anticancer Therapy

Overview
Journal Exp Mol Med
Date 2023 Jul 2
PMID 37394578
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer-associated fibroblasts (CAFs), as a central component of the tumor microenvironment in primary and metastatic tumors, profoundly influence the behavior of cancer cells and are involved in cancer progression through extensive interactions with cancer cells and other stromal cells. Furthermore, the innate versatility and plasticity of CAFs allow their education by cancer cells, resulting in dynamic alterations in stromal fibroblast populations in a context-dependent manner, which highlights the importance of precise assessment of CAF phenotypical and functional heterogeneity. In this review, we summarize the proposed origins and heterogeneity of CAFs as well as the molecular mechanisms regulating the diversity of CAF subpopulations. We also discuss current strategies to selectively target tumor-promoting CAFs, providing insights and perspectives for future research and clinical studies involving stromal targeting.

Citing Articles

Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses.

Zhang B, Zhang Z, Gao J, Lu S, Pang R, Li D iScience. 2025; 28(3):111536.

PMID: 40040813 PMC: 11879607. DOI: 10.1016/j.isci.2024.111536.


Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review.

Liao T, Chen X, Qiu F, Zhang X, Wu F, Zhao Z J Nanobiotechnology. 2025; 23(1):166.

PMID: 40038745 PMC: 11877876. DOI: 10.1186/s12951-025-03217-0.


Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.

Zahoor A, Khazer R, Mehraj I, Gani U, Fayaz F, Khanday F Funct Integr Genomics. 2025; 25(1):50.

PMID: 40024973 DOI: 10.1007/s10142-025-01552-x.


Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.

Horenstein A, Faini A, Morandi F, Ortolan E, Storti P, Giuliani N Front Immunol. 2025; 16:1519300.

PMID: 40013150 PMC: 11860881. DOI: 10.3389/fimmu.2025.1519300.


Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.

Sherpally D, Manne A Cancers (Basel). 2025; 17(4).

PMID: 40002184 PMC: 11853216. DOI: 10.3390/cancers17040589.


References
1.
Chen Y, McAndrews K, Kalluri R . Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021; 18(12):792-804. PMC: 8791784. DOI: 10.1038/s41571-021-00546-5. View

2.
Raghavan S, Winter P, Navia A, Williams H, DenAdel A, Lowder K . Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021; 184(25):6119-6137.e26. PMC: 8822455. DOI: 10.1016/j.cell.2021.11.017. View

3.
Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View

4.
Yoshida G . Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020; 39(1):112. PMC: 7296768. DOI: 10.1186/s13046-020-01611-0. View

5.
Rhim A, Oberstein P, Thomas D, Mirek E, Palermo C, Sastra S . Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25(6):735-47. PMC: 4096698. DOI: 10.1016/j.ccr.2014.04.021. View